JP2014530249A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530249A5 JP2014530249A5 JP2014536344A JP2014536344A JP2014530249A5 JP 2014530249 A5 JP2014530249 A5 JP 2014530249A5 JP 2014536344 A JP2014536344 A JP 2014536344A JP 2014536344 A JP2014536344 A JP 2014536344A JP 2014530249 A5 JP2014530249 A5 JP 2014530249A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- use according
- ibs
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 24
- 229940002612 prodrug Drugs 0.000 claims 18
- 239000000651 prodrug Substances 0.000 claims 18
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 17
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims 13
- 229960002131 palonosetron Drugs 0.000 claims 13
- 239000012458 free base Substances 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 10
- WAXQNWCZJDTGBU-UHFFFAOYSA-N netupitant Chemical compound C=1N=C(N2CCN(C)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WAXQNWCZJDTGBU-UHFFFAOYSA-N 0.000 claims 9
- 229960005163 netupitant Drugs 0.000 claims 9
- 238000011287 therapeutic dose Methods 0.000 claims 9
- 208000004998 Abdominal Pain Diseases 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 6
- 208000004296 neuralgia Diseases 0.000 claims 5
- 208000021722 neuropathic pain Diseases 0.000 claims 5
- 206010010774 Constipation Diseases 0.000 claims 4
- 206010012735 Diarrhoea Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000006186 oral dosage form Substances 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 2
- 206010000059 abdominal discomfort Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 230000010006 flight Effects 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000034347 Faecal incontinence Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 229960000836 amitriptyline Drugs 0.000 claims 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003179 convulsant agent Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002550 fecal effect Effects 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000033001 locomotion Effects 0.000 claims 1
- 239000000014 opioid analgesic Substances 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 239000000902 placebo Substances 0.000 claims 1
- 229940068196 placebo Drugs 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 230000003238 somatosensory effect Effects 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 239000011885 synergistic combination Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548514P | 2011-10-18 | 2011-10-18 | |
| US61/548,514 | 2011-10-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014530249A JP2014530249A (ja) | 2014-11-17 |
| JP2014530249A5 true JP2014530249A5 (en:Method) | 2015-11-19 |
Family
ID=47178220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014536344A Pending JP2014530249A (ja) | 2011-10-18 | 2012-10-10 | ネツピタントおよびパロノセトロンの治療学的組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9358228B2 (en:Method) |
| EP (2) | EP2759298B1 (en:Method) |
| JP (1) | JP2014530249A (en:Method) |
| CN (3) | CN106974912A (en:Method) |
| DK (1) | DK2744497T3 (en:Method) |
| ES (1) | ES2579616T3 (en:Method) |
| HK (1) | HK1198121A1 (en:Method) |
| HU (1) | HUE030811T2 (en:Method) |
| PL (1) | PL2744497T3 (en:Method) |
| PT (1) | PT2744497T (en:Method) |
| WO (1) | WO2013057554A2 (en:Method) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108721214B (zh) * | 2017-04-14 | 2020-06-16 | 和龙 | 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途 |
| TW202428273A (zh) | 2023-01-03 | 2024-07-16 | 瑞士商赫爾辛保健公司 | 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122005000027I2 (de) | 1989-11-28 | 2006-03-16 | Roche Palo Alto Llc | Tricyclische Verbindungen. |
| US5510486A (en) | 1994-07-26 | 1996-04-23 | Syntex (U.S.A.) Inc. | Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one |
| GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
| AU3422800A (en) * | 1999-02-18 | 2000-09-04 | Novartis Ag | Use of 5-ht3 receptor antagonists |
| DK1035115T3 (da) | 1999-02-24 | 2005-01-24 | Hoffmann La Roche | 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister |
| HRP20030003B1 (en) | 2000-07-14 | 2011-01-31 | F. Hoffmann - La Roche Ag | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| BRPI0116121B8 (pt) | 2000-12-14 | 2021-05-25 | F Hoffmannn La Roche Ag | composição de matriz de lipídeo auto-emulsificante para administração oral e seu processo de preparação |
| CN100353946C (zh) * | 2003-01-13 | 2007-12-12 | 戴诺吉药品有限公司 | 治疗功能性肠病的方法 |
| JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
| JO2676B1 (en) * | 2004-04-06 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines |
| ES2576555T3 (es) | 2004-07-01 | 2016-07-08 | Opko Health, Inc. | Derivados de piperidina como antagonistas de NK1 |
| WO2007128056A1 (en) * | 2006-05-03 | 2007-11-15 | Cnsbio Pty Ltd | Methods and composition for treatment of inflammatory pain |
| PL1940366T3 (pl) | 2006-10-24 | 2009-09-30 | Helsinn Healthcare Sa | Miękkie, zawierające chlorowodorek palonosetronu kapsułki o zwiększonej stabilności i biodostępności |
| US20100316678A1 (en) | 2007-06-28 | 2010-12-16 | Cnsbio Pty Ltd. | Combination methods and compositions for treatment of neuropathic pain |
| PH12012500887A1 (en) * | 2009-11-18 | 2016-08-26 | Helsinn Healthcare Sa | Compositions for treating centrally mediated nausea and vomiting |
-
2012
- 2012-10-10 CN CN201610834008.7A patent/CN106974912A/zh active Pending
- 2012-10-10 HU HUE12784677A patent/HUE030811T2/hu unknown
- 2012-10-10 JP JP2014536344A patent/JP2014530249A/ja active Pending
- 2012-10-10 WO PCT/IB2012/002013 patent/WO2013057554A2/en not_active Ceased
- 2012-10-10 PT PT127846772T patent/PT2744497T/pt unknown
- 2012-10-10 PL PL12784677.2T patent/PL2744497T3/pl unknown
- 2012-10-10 US US14/351,113 patent/US9358228B2/en active Active
- 2012-10-10 DK DK12784677.2T patent/DK2744497T3/en active
- 2012-10-10 CN CN201280051509.8A patent/CN103889423B/zh active Active
- 2012-10-10 ES ES12784677.2T patent/ES2579616T3/es active Active
- 2012-10-10 EP EP14165604.1A patent/EP2759298B1/en active Active
- 2012-10-10 CN CN201510670710.XA patent/CN105412110B/zh active Active
- 2012-10-10 EP EP12784677.2A patent/EP2744497B1/en active Active
-
2014
- 2014-08-14 HK HK14110976.1A patent/HK1198121A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5399898B2 (ja) | 神経因性疼痛の治療用カンナビノイド | |
| JP2023171776A (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| CN104968368A (zh) | 固溶体组合物及其在剧痛中的用途 | |
| JP2017510607A5 (en:Method) | ||
| JP2013541583A5 (en:Method) | ||
| JP2017132791A (ja) | 組み合わせ組成物 | |
| AU2022202218A1 (en) | Combination Therapy Using Acamprosate And D-Cycloserine | |
| CA2735834C (en) | Composition comprising ibuprofen and paracetamol to treat pain caused by osteoarthritis and rheumatoid arthritis | |
| JP2016505050A5 (en:Method) | ||
| HRP20240812T1 (hr) | Oblici doziranja i terapijska primjena l-4-klorokinurenina | |
| JP2014530249A5 (en:Method) | ||
| JP2020527156A5 (en:Method) | ||
| CN115835862A (zh) | 治疗阿尔茨海默病的组合及其应用 | |
| JP2014530249A (ja) | ネツピタントおよびパロノセトロンの治療学的組合せ | |
| CN104117065B (zh) | 一种基于青藤碱的用于镇痛的药物组合产品 | |
| CN110279691A (zh) | 一种外科术后护理镇痛药物及其用途 | |
| UA112652C2 (uk) | Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції | |
| CN117243948A (zh) | 包含瑞香素的组合物在制备风湿性关节炎药物中的应用 | |
| JPWO2009025091A1 (ja) | 線維筋痛症治療用医薬組成物 | |
| JP2022541634A (ja) | 疼痛に関連する睡眠障害を治療する方法 | |
| Peterson | Postherpetic neuralgia in the elderly: Debilitating and difficult to manage | |
| EA201892706A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| KR20200088861A (ko) | 우울증의 예방 또는 치료용 벤조익산 또는 이의 염 및 유도체 | |
| Barthunia et al. | Pregabalin and its Efficacy in Trigeminal Neuralgia–A Review | |
| CN103301124A (zh) | 一种治疗癫痫的药物组合物 |